Loading data
PSIXNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 722.41 m USD | 475.97 m USD | 458.97 m USD | 481.33 m USD | 456.26 m USD |
| Cost of revenue | 537.51 m USD | 335.43 m USD | 353.11 m USD | 392.77 m USD | 414.98 m USD |
| Gross profit | 184.9 m USD | 140.54 m USD | 105.86 m USD | 88.56 m USD | 41.27 m USD |
| Research and development expense | 18.16 m USD | 20.06 m USD | 19.46 m USD | 18.9 m USD | 22.44 m USD |
| Operating profit | 109.71 m USD | 81.64 m USD | 44.28 m USD | 24.6 m USD | -41.57 m USD |
| Interest expense | — | — | 17.07 m USD | 13.03 m USD | 7.31 m USD |
| Profit before tax | 103.4 m USD | 70.2 m USD | 27.21 m USD | 11.57 m USD | -48.88 m USD |
| Income tax expense | -10.62 m USD | 922 k USD | 900 k USD | 304 k USD | -406 k USD |
| Net income (reported basis) | 113.99 m USD | 69.28 m USD | 26.31 m USD | 11.27 m USD | -48.47 m USD |
| Basic earnings per share | 4.95 USD/share | 3.01 USD/share | 1.15 USD/share | 0.49 USD/share | -2.12 USD/share |
| Diluted earnings per share | 4.94 USD/share | 3.01 USD/share | 1.15 USD/share | 0.49 USD/share | -2.12 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.